Premenopausal breast cancer patients treated with a gonadotropin-releasing hormone analog alone or in combination with an aromatase inhibitor: a comparative endocrine study.

Celio L, Martinetti A, Ferrari L, Buzzoni R, Mariani L, Miceli R, Seregni E, Procopio G, Cassata A, Bombardieri E, Bajetta E

Anticancer research1 May 1999Cited by 33 (Europe PMC)

PMID10472341PepBankPUB-10472341

Publisher pageAsk about this study

Jump to 15 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study15

5 results from studies that gave the peptide. 5 results from people.

01HumanRandomized controlled trialEfficacy outcome
In premenopausal breast cancer patients, triptorelin alone reduced estradiol from baseline after four weeks.
In plain wordsIn premenopausal breast cancer patients, triptorelin alone reduced estradiol compared with baseline.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseEstradiol suppression
Study
n = 10
Comparator
Baseline
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
3.75 mg monthly · intramuscular · four weeksAs given in this study (human).
Measurements
Estradiol decrease
86.9%
triptorelin alone
Source sentences
Summary
In comparison with baseline values, after four weeks of treatment the estradiol levels decreased by an average of 86.9% (95% CI, 70.5-94.2%) in the group treated with triptorelin alone
2 context sentences(design, population, supporting numbers)
Summary · context
Twenty-one premenopausal women with advanced breast cancer were randomised to receive the GnRH analog triptorelin (3.75 mg i.m. monthly; n = 10) alone or in combination with the aromatase inhibitor formestane (4-OHA, 500 mg i.m. fortnightly; n = 11) to compare the effect of both treatments on the pa…
Summary · context
Therefore, serum estrogen, gonadotropin and sex hormone-binding globulin (SHBG) levels were investigated before the start of treatment and subsequently over a three-month period.
Report a problemFND-1047234101
02HumanRandomized controlled trialEfficacy outcome
In premenopausal breast cancer patients, triptorelin alone reduced estrone from baseline.
In plain wordsIn premenopausal breast cancer patients, triptorelin alone reduced estrone compared with baseline.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseEstrone suppression
Study
n = 10
Comparator
Baseline
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
3.75 mg monthly · intramuscular · four weeksAs given in this study (human).
Measurements
Estrone decrease
48.5%
triptorelin alone
Source sentences
Summary
the respective figures for estrone were 48.5% (95% CI, 27.5-63.5%) and 70.4% (95% CI, 52.3-81.6%; P = 0.0007)
2 context sentences(design, population, supporting numbers)
Summary · context
Twenty-one premenopausal women with advanced breast cancer were randomised to receive the GnRH analog triptorelin (3.75 mg i.m. monthly; n = 10) alone or in combination with the aromatase inhibitor formestane (4-OHA, 500 mg i.m. fortnightly; n = 11) to compare the effect of both treatments on the pa…
Summary · context
Therefore, serum estrogen, gonadotropin and sex hormone-binding globulin (SHBG) levels were investigated before the start of treatment and subsequently over a three-month period.
Report a problemFND-1047234103
03HumanRandomized controlled trialEfficacy outcome
In premenopausal breast cancer patients, triptorelin alone reduced estrone sulfate from baseline.
In plain wordsIn premenopausal breast cancer patients, triptorelin alone reduced estrone sulfate compared with baseline.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseEstrone sulfate suppression
Study
n = 10
Comparator
Baseline
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
3.75 mg monthly · intramuscular · four weeksAs given in this study (human).
Measurements
Estrone sulfate decrease
56.7%
triptorelin alone
Source sentences
Summary
and for estrone sulfate 56.7% (95% CI, 40-68.8%) and 80.5% (95% CI, 69.4-87.6%; P = 0.0055).
2 context sentences(design, population, supporting numbers)
Summary · context
Twenty-one premenopausal women with advanced breast cancer were randomised to receive the GnRH analog triptorelin (3.75 mg i.m. monthly; n = 10) alone or in combination with the aromatase inhibitor formestane (4-OHA, 500 mg i.m. fortnightly; n = 11) to compare the effect of both treatments on the pa…
Summary · context
Therefore, serum estrogen, gonadotropin and sex hormone-binding globulin (SHBG) levels were investigated before the start of treatment and subsequently over a three-month period.
Report a problemFND-1047234105
04HumanRandomized controlled trialEfficacy outcome
In premenopausal breast cancer patients, triptorelin alone produced a slight delayed SHBG decrease.
In plain wordsIn premenopausal breast cancer patients, SHBG decreased slightly and late during triptorelin alone.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseSHBG decrease
Study
n = 10
Comparator
Baseline
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
3.75 mg monthly · intramuscular · three monthsAs given in this study (human).
Source sentences
Summary
No difference was observed between the groups in terms of gonadotropin suppression; both treatment modalities led to a slight but delayed decrease in SHBG levels.
2 context sentences(design, population, supporting numbers)
Summary · context
Twenty-one premenopausal women with advanced breast cancer were randomised to receive the GnRH analog triptorelin (3.75 mg i.m. monthly; n = 10) alone or in combination with the aromatase inhibitor formestane (4-OHA, 500 mg i.m. fortnightly; n = 11) to compare the effect of both treatments on the pa…
Summary · context
Therefore, serum estrogen, gonadotropin and sex hormone-binding globulin (SHBG) levels were investigated before the start of treatment and subsequently over a three-month period.
Report a problemFND-1047234111
05HumanRandomized controlled trialEfficacy outcome
In premenopausal breast cancer patients, three patients receiving triptorelin alone experienced tumor regression.
In plain wordsIn premenopausal breast cancer patients, three receiving triptorelin alone had tumor regression.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Not applicableTumor regression
Study
n = 10
Outcome group
Tumor growth · Cancer
Studied dose
3.75 mg monthly · intramuscularAs given in this study (human).
Measurements
Tumor regression
3 patients
triptorelin alone
Source sentences
Summary
Three of the patients treated with triptorelin alone experienced tumor regression compared with four patients in the combination group.
2 context sentences(design, population, supporting numbers)
Summary · context
Twenty-one premenopausal women with advanced breast cancer were randomised to receive the GnRH analog triptorelin (3.75 mg i.m. monthly; n = 10) alone or in combination with the aromatase inhibitor formestane (4-OHA, 500 mg i.m. fortnightly; n = 11) to compare the effect of both treatments on the pa…
Summary · context
Therefore, serum estrogen, gonadotropin and sex hormone-binding globulin (SHBG) levels were investigated before the start of treatment and subsequently over a three-month period.
Report a problemFND-1047234113

Studies that did not test the peptide alone10

In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Triptorelin (Trelstar, Decapeptyl).

06HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneRandomized controlled trialEfficacy outcome
In premenopausal breast cancer patients, triptorelin plus formestane produced greater estradiol suppression than triptorelin alone.
In plain wordsIn premenopausal breast cancer patients, triptorelin plus formestane suppressed estradiol more than triptorelin alone.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreaseBetween-group estradiol suppression
Study
n = 21
Comparator
Triptorelin alone
Outcome group
Sex hormones and fertility · Endocrine and hormones
Measurements
Estradiol decrease
86.9%
triptorelin alone
Estradiol decrease
97.3%
combination
Source sentences
Summary
In comparison with baseline values, after four weeks of treatment the estradiol levels decreased by an average of 86.9% (95% CI, 70.5-94.2%) in the group treated with triptorelin alone and by 97.3% (95% CI, 94.1-98.8%; P = 0.0422) in the combination group;
2 context sentences(design, population, supporting numbers)
Summary · context
Twenty-one premenopausal women with advanced breast cancer were randomised to receive the GnRH analog triptorelin (3.75 mg i.m. monthly; n = 10) alone or in combination with the aromatase inhibitor formestane (4-OHA, 500 mg i.m. fortnightly; n = 11) to compare the effect of both treatments on the pa…
Summary · context
Therefore, serum estrogen, gonadotropin and sex hormone-binding globulin (SHBG) levels were investigated before the start of treatment and subsequently over a three-month period.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-1047234107
07HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneRandomized controlled trialEfficacy outcome
In premenopausal breast cancer patients, triptorelin plus formestane produced greater estrone suppression than triptorelin alone.
In plain wordsIn premenopausal breast cancer patients, triptorelin plus formestane suppressed estrone more than triptorelin alone.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreaseBetween-group estrone suppression
Study
n = 21
Comparator
Triptorelin alone
Outcome group
Sex hormones and fertility · Endocrine and hormones
Measurements
Estrone decrease
48.5%
triptorelin alone
Estrone decrease
70.4%
combination
Source sentences
Summary
the respective figures for estrone were 48.5% (95% CI, 27.5-63.5%) and 70.4% (95% CI, 52.3-81.6%; P = 0.0007)
2 context sentences(design, population, supporting numbers)
Summary · context
Twenty-one premenopausal women with advanced breast cancer were randomised to receive the GnRH analog triptorelin (3.75 mg i.m. monthly; n = 10) alone or in combination with the aromatase inhibitor formestane (4-OHA, 500 mg i.m. fortnightly; n = 11) to compare the effect of both treatments on the pa…
Summary · context
Therefore, serum estrogen, gonadotropin and sex hormone-binding globulin (SHBG) levels were investigated before the start of treatment and subsequently over a three-month period.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-1047234108
08HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneRandomized controlled trialEfficacy outcome
In premenopausal breast cancer patients, triptorelin plus formestane produced greater estrone sulfate suppression than triptorelin alone.
In plain wordsIn premenopausal breast cancer patients, triptorelin plus formestane suppressed estrone sulfate more than triptorelin alone.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreaseBetween-group estrone sulfate suppression
Study
n = 21
Comparator
Triptorelin alone
Outcome group
Sex hormones and fertility · Endocrine and hormones
Measurements
Estrone sulfate decrease
56.7%
triptorelin alone
Estrone sulfate decrease
80.5%
combination
Source sentences
Summary
and for estrone sulfate 56.7% (95% CI, 40-68.8%) and 80.5% (95% CI, 69.4-87.6%; P = 0.0055).
2 context sentences(design, population, supporting numbers)
Summary · context
Twenty-one premenopausal women with advanced breast cancer were randomised to receive the GnRH analog triptorelin (3.75 mg i.m. monthly; n = 10) alone or in combination with the aromatase inhibitor formestane (4-OHA, 500 mg i.m. fortnightly; n = 11) to compare the effect of both treatments on the pa…
Summary · context
Therefore, serum estrogen, gonadotropin and sex hormone-binding globulin (SHBG) levels were investigated before the start of treatment and subsequently over a three-month period.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-1047234109
09HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneRandomized controlled trialEfficacy outcome
In premenopausal breast cancer patients, gonadotropin suppression did not differ between triptorelin plus formestane and triptorelin alone.
In plain wordsIn premenopausal breast cancer patients, gonadotropin suppression was similar with triptorelin plus formestane and triptorelin alone.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeGonadotropin suppression
Study
n = 21
Comparator
Triptorelin alone
Outcome group
Sex hormones and fertility · Endocrine and hormones
Source sentences
Summary
No difference was observed between the groups in terms of gonadotropin suppression; both treatment modalities led to a slight but delayed decrease in SHBG levels.
2 context sentences(design, population, supporting numbers)
Summary · context
Twenty-one premenopausal women with advanced breast cancer were randomised to receive the GnRH analog triptorelin (3.75 mg i.m. monthly; n = 10) alone or in combination with the aromatase inhibitor formestane (4-OHA, 500 mg i.m. fortnightly; n = 11) to compare the effect of both treatments on the pa…
Summary · context
Therefore, serum estrogen, gonadotropin and sex hormone-binding globulin (SHBG) levels were investigated before the start of treatment and subsequently over a three-month period.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-1047234110
10HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneRandomized controlled trialEfficacy outcome
In premenopausal breast cancer patients, triptorelin plus formestane reduced estradiol from baseline.
In plain wordsIn premenopausal breast cancer patients, triptorelin plus formestane reduced estradiol compared with baseline.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseEstradiol suppression with combination
Study
n = 11
Comparator
Baseline
Outcome group
Sex hormones and fertility · Endocrine and hormones
Measurements
Estradiol decrease
97.3%
combination
Source sentences
Summary
In comparison with baseline values, after four weeks of treatment the estradiol levels decreased by an average of 86.9% (95% CI, 70.5-94.2%) in the group treated with triptorelin alone and by 97.3% (95% CI, 94.1-98.8%; P = 0.0422) in the combination group;
2 context sentences(design, population, supporting numbers)
Summary · context
Twenty-one premenopausal women with advanced breast cancer were randomised to receive the GnRH analog triptorelin (3.75 mg i.m. monthly; n = 10) alone or in combination with the aromatase inhibitor formestane (4-OHA, 500 mg i.m. fortnightly; n = 11) to compare the effect of both treatments on the pa…
Summary · context
Therefore, serum estrogen, gonadotropin and sex hormone-binding globulin (SHBG) levels were investigated before the start of treatment and subsequently over a three-month period.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-1047234102
11HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneRandomized controlled trialEfficacy outcome
In premenopausal breast cancer patients, triptorelin plus formestane reduced estrone from baseline.
In plain wordsIn premenopausal breast cancer patients, triptorelin plus formestane reduced estrone compared with baseline.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseEstrone suppression with combination
Study
n = 11
Comparator
Baseline
Outcome group
Sex hormones and fertility · Endocrine and hormones
Measurements
Estrone decrease
70.4%
combination
Source sentences
Summary
the respective figures for estrone were 48.5% (95% CI, 27.5-63.5%) and 70.4% (95% CI, 52.3-81.6%; P = 0.0007)
2 context sentences(design, population, supporting numbers)
Summary · context
Twenty-one premenopausal women with advanced breast cancer were randomised to receive the GnRH analog triptorelin (3.75 mg i.m. monthly; n = 10) alone or in combination with the aromatase inhibitor formestane (4-OHA, 500 mg i.m. fortnightly; n = 11) to compare the effect of both treatments on the pa…
Summary · context
Therefore, serum estrogen, gonadotropin and sex hormone-binding globulin (SHBG) levels were investigated before the start of treatment and subsequently over a three-month period.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-1047234104
12HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneRandomized controlled trialEfficacy outcome
In premenopausal breast cancer patients, triptorelin plus formestane reduced estrone sulfate from baseline.
In plain wordsIn premenopausal breast cancer patients, triptorelin plus formestane reduced estrone sulfate compared with baseline.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseEstrone sulfate suppression with combination
Study
n = 11
Comparator
Baseline
Outcome group
Sex hormones and fertility · Endocrine and hormones
Measurements
Estrone sulfate decrease
80.5%
combination
Source sentences
Summary
and for estrone sulfate 56.7% (95% CI, 40-68.8%) and 80.5% (95% CI, 69.4-87.6%; P = 0.0055).
2 context sentences(design, population, supporting numbers)
Summary · context
Twenty-one premenopausal women with advanced breast cancer were randomised to receive the GnRH analog triptorelin (3.75 mg i.m. monthly; n = 10) alone or in combination with the aromatase inhibitor formestane (4-OHA, 500 mg i.m. fortnightly; n = 11) to compare the effect of both treatments on the pa…
Summary · context
Therefore, serum estrogen, gonadotropin and sex hormone-binding globulin (SHBG) levels were investigated before the start of treatment and subsequently over a three-month period.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-1047234106
13HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneRandomized controlled trialEfficacy outcome
In premenopausal breast cancer patients, triptorelin plus formestane produced a slight delayed SHBG decrease.
In plain wordsIn premenopausal breast cancer patients, SHBG decreased slightly and late during triptorelin plus formestane.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseSHBG decrease with combination
Study
n = 11
Comparator
Baseline
Outcome group
Sex hormones and fertility · Endocrine and hormones
Source sentences
Summary
No difference was observed between the groups in terms of gonadotropin suppression; both treatment modalities led to a slight but delayed decrease in SHBG levels.
2 context sentences(design, population, supporting numbers)
Summary · context
Twenty-one premenopausal women with advanced breast cancer were randomised to receive the GnRH analog triptorelin (3.75 mg i.m. monthly; n = 10) alone or in combination with the aromatase inhibitor formestane (4-OHA, 500 mg i.m. fortnightly; n = 11) to compare the effect of both treatments on the pa…
Summary · context
Therefore, serum estrogen, gonadotropin and sex hormone-binding globulin (SHBG) levels were investigated before the start of treatment and subsequently over a three-month period.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-1047234112
14HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneRandomized controlled trialEfficacy outcome
In premenopausal breast cancer patients, four receiving triptorelin plus formestane experienced tumor regression.
In plain wordsIn premenopausal breast cancer patients, four receiving triptorelin plus formestane had tumor regression.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Not applicableTumor regression with combination
Study
n = 11
Outcome group
Tumor growth · Cancer
Measurements
Tumor regression
4 patients
combination
Source sentences
Summary
Three of the patients treated with triptorelin alone experienced tumor regression compared with four patients in the combination group.
2 context sentences(design, population, supporting numbers)
Summary · context
Twenty-one premenopausal women with advanced breast cancer were randomised to receive the GnRH analog triptorelin (3.75 mg i.m. monthly; n = 10) alone or in combination with the aromatase inhibitor formestane (4-OHA, 500 mg i.m. fortnightly; n = 11) to compare the effect of both treatments on the pa…
Summary · context
Therefore, serum estrogen, gonadotropin and sex hormone-binding globulin (SHBG) levels were investigated before the start of treatment and subsequently over a three-month period.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-1047234114
15HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneRandomized controlled trialSafety outcome
In premenopausal breast cancer patients, no appreciable side effects occurred with triptorelin plus formestane.
In plain wordsIn premenopausal breast cancer patients, triptorelin plus formestane produced no appreciable side effects.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Not applicableAppreciable side effects with combination
Study
n = 11
Outcome group
Adverse events · Whole body
Source sentences
Summary
No appreciable side effects of the combination therapy were observed.
2 context sentences(design, population, supporting numbers)
Summary · context
Twenty-one premenopausal women with advanced breast cancer were randomised to receive the GnRH analog triptorelin (3.75 mg i.m. monthly; n = 10) alone or in combination with the aromatase inhibitor formestane (4-OHA, 500 mg i.m. fortnightly; n = 11) to compare the effect of both treatments on the pa…
Summary · context
Therefore, serum estrogen, gonadotropin and sex hormone-binding globulin (SHBG) levels were investigated before the start of treatment and subsequently over a three-month period.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-1047234115

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.

Premenopausal breast cancer patients treated with a gonadotropin-releasing hormone analog alone or in combination with an aromatase inhibitor: a comparative endocrine study.

Summary

Results from this study15

Studies that did not test the peptide alone10

Version history

Subjects

Publication types

MeSH terms